SCHEMBL4979459

SCHEMBL4979459

C=CCc1cc(C(=O)N(CC)CC)ccc1OC

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.58
HSP90AB1 P08238 3/20 0.58
CYP1A2 P05177 1/20 0.58
BLM P54132 1/20 0.58
PTPN1 P18031 3/20 0.53
ALOX5 P09917 3/20 0.46
ELANE P08246 2/20 0.46
GABRA1 P14867 2/20 0.45
CNR2 P34972 2/20 0.45
GABRB2 P47870 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
PTGS1 P23219 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4982316 0.86 PTPN1 (0.55) PTPN1ALOX5ELANEGABRA1CNR2
SCHEMBL4982250 0.83 PTPN1 (0.60) PTPN1ALOX5ELANEGABRA1CNR2
SCHEMBL9733519 0.82 PTPN1 (0.56) PTPN1ALOX5ELANEGABRA1CNR2
SCHEMBL4981784 0.81 ALDH1A1 (0.61) PTPN1ALOX5ALDH1A1MEN1KMT2A
SCHEMBL3542900 0.80 PTPN1 (0.57) HSP90AA1PTPN1ALOX5ELANEGABRA1
SCHEMBL4979174 0.80 HSD17B2 (0.57) PTPN1ALOX5ELANEGABRA1CNR2
SCHEMBL13216464 0.79 HSP90AA1 (0.77) HSP90AA1HSP90AB1CYP1A2BLMELANE
SCHEMBL9349305 0.78 PTPN1 (0.55) PTPN1ALOX5ELANEGABRA1CNR2
SCHEMBL24476677 0.76 HSP90AA1 (0.66) HSP90AA1HSP90AB1CYP1A2BLMELANE
Ethamivan SCHEMBL29351657 0.74 HSP90AA1 (1.00) HSP90AA1HSP90AB1CYP1A2BLMELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B HSP90AA1 1548/4885HSP90AB1 1253/4885CYP1A2 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.